Reduction of Immune Activation and Partial Recovery of Staphylococcal Enterotoxin B-Induced Cytokine Production After Switching to an Integrase Strand Transfer Inhibitor-Containing Regimen: Results from an Observational Cohort Study.


Journal

Clinical drug investigation
ISSN: 1179-1918
Titre abrégé: Clin Drug Investig
Pays: New Zealand
ID NLM: 9504817

Informations de publication

Date de publication:
Dec 2019
Historique:
pubmed: 19 9 2019
medline: 29 1 2020
entrez: 19 9 2019
Statut: ppublish

Résumé

Despite integrase strand transfer inhibitor (INSTI)-containing regimens now being considered a preferred option for both initial therapy and switching strategies in virologically suppressed patients, their effects on lymphocyte phenotypes and functions in the course of effective combination antiretroviral therapy (cART) are still unclear. Thus, we investigated the effect of a 24-week elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (EVG/c/FTC/TDF) regimen on the T cell compartment and HIV reservoirs in HIV-infected patients switching from a suppressive protease inhibitor-based regimen. Thirty HIV-positive patients receiving suppressive tenofovir disoproxil fumarate/emtricitabine (TDF + FTC) (for a median of 5 years) in association with either darunavir/ritonavir (DVR/r) (47%) or atazanavir/ritonavir (ATV/r) (53%) were followed up for 24 weeks after switching to EVG/c/FTC/TDF. At baseline (week 0 [W0]) and after 12 (W12) and 24 (W24) weeks we analyzed HLA-DR (human leukocyte antigen-DR isotype)/CD38/Ki67/CCR7 (C-C chemokine receptor type 7)/CD45RA/CD127/PD-1 (programmed cell death-1) on CD4/CD8, interferon (IFN)-γ/interleukin (IL)-2 after HIV/Staphylococcal enterotoxin B (SEB) exposure (flow cytometry); total, integrated, and unintegrated HIV-DNA; and residual low-level HIV viremia (quantitative polymerase chain reaction [qPCR]). While EVG/c/FTC/TDF introduction resulted in a stable CD4+ and CD8+ count, residual low-level HIV-RNA viremia, and HIV reservoirs, we observed a significant reduction in both activated CD4+ (p = 0.016) and CD8+ (p = 0.048) T cells, coupled with an increase in IL-2 and IFN-γ release by CD4+ and CD8+ effector memory T cells, and a decrease in cytokine production by terminally differentiated CD8+ T cells following SEB exposure. Furthermore, the magnitude of the reduction of activated HLA-DR + CD38 + CD8+ T cells (r = - 0.63, p = 0.014) inversely correlates with the amount of total HIV-DNA at W24. Our data show a favorable effect of EVG/c/FTC/TDF switch to preserve immune activation-driven damage to T cell homeostasis, restore the multifunctional properties of effector T cells, and possibly contain cell-associated HIV viral burden in already virologically suppressed patients.

Sections du résumé

BACKGROUND AND OBJECTIVE OBJECTIVE
Despite integrase strand transfer inhibitor (INSTI)-containing regimens now being considered a preferred option for both initial therapy and switching strategies in virologically suppressed patients, their effects on lymphocyte phenotypes and functions in the course of effective combination antiretroviral therapy (cART) are still unclear. Thus, we investigated the effect of a 24-week elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (EVG/c/FTC/TDF) regimen on the T cell compartment and HIV reservoirs in HIV-infected patients switching from a suppressive protease inhibitor-based regimen.
METHODS METHODS
Thirty HIV-positive patients receiving suppressive tenofovir disoproxil fumarate/emtricitabine (TDF + FTC) (for a median of 5 years) in association with either darunavir/ritonavir (DVR/r) (47%) or atazanavir/ritonavir (ATV/r) (53%) were followed up for 24 weeks after switching to EVG/c/FTC/TDF. At baseline (week 0 [W0]) and after 12 (W12) and 24 (W24) weeks we analyzed HLA-DR (human leukocyte antigen-DR isotype)/CD38/Ki67/CCR7 (C-C chemokine receptor type 7)/CD45RA/CD127/PD-1 (programmed cell death-1) on CD4/CD8, interferon (IFN)-γ/interleukin (IL)-2 after HIV/Staphylococcal enterotoxin B (SEB) exposure (flow cytometry); total, integrated, and unintegrated HIV-DNA; and residual low-level HIV viremia (quantitative polymerase chain reaction [qPCR]).
RESULTS RESULTS
While EVG/c/FTC/TDF introduction resulted in a stable CD4+ and CD8+ count, residual low-level HIV-RNA viremia, and HIV reservoirs, we observed a significant reduction in both activated CD4+ (p = 0.016) and CD8+ (p = 0.048) T cells, coupled with an increase in IL-2 and IFN-γ release by CD4+ and CD8+ effector memory T cells, and a decrease in cytokine production by terminally differentiated CD8+ T cells following SEB exposure. Furthermore, the magnitude of the reduction of activated HLA-DR + CD38 + CD8+ T cells (r = - 0.63, p = 0.014) inversely correlates with the amount of total HIV-DNA at W24.
CONCLUSIONS CONCLUSIONS
Our data show a favorable effect of EVG/c/FTC/TDF switch to preserve immune activation-driven damage to T cell homeostasis, restore the multifunctional properties of effector T cells, and possibly contain cell-associated HIV viral burden in already virologically suppressed patients.

Identifiants

pubmed: 31531832
doi: 10.1007/s40261-019-00840-2
pii: 10.1007/s40261-019-00840-2
pmc: PMC6842342
doi:

Substances chimiques

Anti-HIV Agents 0
Cytokines 0
Enterotoxins 0
HIV Protease Inhibitors 0
enterotoxin B, staphylococcal 39424-53-8

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

1239-1249

Subventions

Organisme : Gilead Sciences
ID : IN-IT-236-1320

Références

PLoS Pathog. 2016 Jan 21;12(1):e1005381
pubmed: 26795282
Curr HIV/AIDS Rep. 2017 Jun;14(3):93-100
pubmed: 28434169
J Immunol Res. 2014;2014:569819
pubmed: 25025081
J Infect Dis. 2016 Oct 1;214 Suppl 2:S44-50
pubmed: 27625430
Curr Opin HIV AIDS. 2014 Jul;9(4):302-8
pubmed: 24824891
Antivir Ther. 2017;22(1):71-75
pubmed: 27740536
Clin Infect Dis. 2015 Aug 15;61(4):651-60
pubmed: 25904376
J Infect Dis. 2011 Mar 15;203(6):780-90
pubmed: 21252259
Clin Infect Dis. 2019 Sep 27;69(8):1320-1328
pubmed: 30590412
AIDS. 2012 Nov 28;26(18):2315-26
pubmed: 23018438
Antiviral Res. 2016 Aug;132:59-65
pubmed: 27216995
AIDS. 2010 Oct 23;24(16):2451-60
pubmed: 20827162
Antivir Ther. 2012;17(2):355-64
pubmed: 22290239
J Int AIDS Soc. 2017 Mar 8;20(1):21526
pubmed: 28362071
Virulence. 2016 Apr 2;7(3):320-8
pubmed: 26950194
AIDS. 2013 Jun 1;27(9):1413-9
pubmed: 23945503
J Antimicrob Chemother. 2017 Sep 1;72(9):2681-2683
pubmed: 28582509
Curr Opin HIV AIDS. 2016 Mar;11(2):216-25
pubmed: 26599166
J Infect Dis. 2011 Oct 15;204(8):1217-26
pubmed: 21917895
Clin Infect Dis. 2012 Feb 1;54(3):451-3
pubmed: 22016501
PLoS One. 2013 Dec 18;8(12):e81355
pubmed: 24367482
PLoS One. 2014 Nov 03;9(11):e111919
pubmed: 25364909
HIV Med. 2014 Aug;15(7):431-41
pubmed: 24506429
Thromb Res. 2014 May;133 Suppl 1:S21-4
pubmed: 24759134
Antiviral Res. 2018 Dec;160:165-174
pubmed: 30420339
HIV Med. 2017 Apr;18(4):256-266
pubmed: 27578404
AIDS. 2018 Jul 31;32(12):1651-1660
pubmed: 29762168
HIV Med. 2018 Jun 22;:null
pubmed: 29932298
Curr Opin HIV AIDS. 2016 Mar;11(2):234-41
pubmed: 26575148
J Infect Dis. 2014 Oct 15;210(8):1228-38
pubmed: 24755434
PLoS One. 2015 Oct 02;10(10):e0139474
pubmed: 26430882
J Int AIDS Soc. 2013 Jan 30;16:17344
pubmed: 23374857
Proc Natl Acad Sci U S A. 2007 Oct 9;104(41):16233-8
pubmed: 17911249
Nat Med. 2010 Apr;16(4):460-5
pubmed: 20228817
HIV Med. 2016 Oct;17 Suppl 5:3-16
pubmed: 27714978
J Acquir Immune Defic Syndr. 2000 Feb 1;23(2):145-51
pubmed: 10737429
Blood. 2006 Jun 15;107(12):4781-9
pubmed: 16467198
J Infect Dis. 2013 Sep;208(6):892-7
pubmed: 23801606
J Infect Dis. 2015 Aug 1;212(3):345-54
pubmed: 25583168
Blood. 2004 Feb 1;103(3):966-72
pubmed: 12958069
Immunity. 2013 Oct 17;39(4):633-45
pubmed: 24138880
Crit Care. 2011 Aug 26;15(4):R202
pubmed: 21871086
Clin Infect Dis. 2010 Mar 15;50(6):912-9
pubmed: 20156060
Eur J Immunol. 2004 Dec;34(12):3525-33
pubmed: 15484193

Auteurs

Esther Merlini (E)

Department of Health Sciences, Clinic of Infectious Diseases, ASST Santi Paolo e Carlo, University of Milan, via A. di Rudinì, 8, 20142, Milan, Italy.

Federico A Cazzaniga (FA)

Department of Health Sciences, Clinic of Infectious Diseases, ASST Santi Paolo e Carlo, University of Milan, via A. di Rudinì, 8, 20142, Milan, Italy.
Unit of Neuropathology and Neurology, Fondazione IRCCS, Istituto Neurologico Carlo Besta, Milan, Italy.

Anna Casabianca (A)

Department of Biomolecular Sciences, University of Urbino "Carlo Bo", Urbino, Italy.

Chiara Orlandi (C)

Department of Biomolecular Sciences, University of Urbino "Carlo Bo", Urbino, Italy.

Mauro Magnani (M)

Department of Biomolecular Sciences, University of Urbino "Carlo Bo", Urbino, Italy.

Giuseppe Ancona (G)

Department of Health Sciences, Clinic of Infectious Diseases, ASST Santi Paolo e Carlo, University of Milan, via A. di Rudinì, 8, 20142, Milan, Italy.

Camilla Tincati (C)

Department of Health Sciences, Clinic of Infectious Diseases, ASST Santi Paolo e Carlo, University of Milan, via A. di Rudinì, 8, 20142, Milan, Italy.

Antonella d'Arminio Monforte (A)

Department of Health Sciences, Clinic of Infectious Diseases, ASST Santi Paolo e Carlo, University of Milan, via A. di Rudinì, 8, 20142, Milan, Italy.

Giulia Marchetti (G)

Department of Health Sciences, Clinic of Infectious Diseases, ASST Santi Paolo e Carlo, University of Milan, via A. di Rudinì, 8, 20142, Milan, Italy. giulia.marchetti@unimi.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH